Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.
Epidermolysis bullosa acquisita is a rare autoimmune subepidermal blistering disease, often resisting current treatments, especially systemic corticosteroids. We report a patient having a bullous pemphigoid who relapsed with clinical and immunological features of inflammatory epidermolysis bullosa acquisita. An anti-CD20 monoclonal antibody (rituximab) was proposed because of resistance to high-dose steroids and other immunosuppressive agents. The disease dramatically improved within a few weeks following rituximab infusion allowing the decrease in steroid therapy. Our case illustrates also the possible evolution from bullous pemphigoid to epidermolysis bullosa acquisita that should be suspected when clinical atypia occurs or in case of corticosteroid resistance.
Wallet-Faber
N
N
Service de Dermatologie et Vénéréologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
Franck
N
N
Batteux
F
F
Mateus
C
C
Gilbert
D
D
Carlotti
A
A
Avril
M F
MF
Dupin
N
N
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D016107:Epidermolysis Bullosa Acquisita / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D010391:Pemphigoid, Bullous / Q000150:complications* / Q000188:drug therapy; D012008:Recurrence; D000069283:Rituximab